Rifabutin

- CAS No.
- 72559-06-9
- Chemical Name:
- Rifabutin
- Synonyms
- Rifabutin-d7;Ansamycin;RIFABUTINE;lm427;RIFABUTIN;Mycobutin;Rifabatin;Levobutin;Ansatipine;Lifu pudding
- CBNumber:
- CB0702764
- Molecular Formula:
- C46H62N4O11
- Molecular Weight:
- 847
- MOL File:
- 72559-06-9.mol
- MSDS File:
- SDS
- Modify Date:
- 2025/1/27 9:38:02
Melting point | 169-171°C |
---|---|
Boiling point | 969.6±65.0 °C(Predicted) |
Density | 1.33±0.1 g/cm3(Predicted) |
storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
solubility | DMSO: >5mg/mL |
form | powder |
pka | 3.31±0.70(Predicted) |
color | Dark Red to Dark Purple |
Water Solubility | 0.19g/L(temperature not stated) |
BCS Class | 2 |
Stability | Hygroscopic and Light Sensitive |
InChIKey | ATEBXHFBFRCZMA-VXTBVIBXSA-N |
CAS DataBase Reference | 72559-06-9 |
SAFETY
Risk and Safety Statements
Symbol(GHS) | ![]() GHS07 |
---|---|
Signal word | Warning |
Hazard statements | H302-H319 |
Precautionary statements | P305+P351+P338 |
WGK Germany | 3 |
RTECS | VJ6700000 |
HS Code | 2941906000 |
Hazardous Substances Data | 72559-06-9(Hazardous Substances Data) |
Rifabutin price More Price(5)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Sigma-Aldrich(India) | R3530 | Rifabutin >98% (HPLC), powder | 72559-06-9 | 5MG | ₹10597.68 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | R3530 | Rifabutin >98% (HPLC), powder | 72559-06-9 | 25MG | ₹42661.33 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | PHR2611 | Rifabutin Pharmaceutical Secondary Standard; Certified Reference Material | 72559-06-9 | 100MG | ₹22764.98 | 2022-06-14 | Buy |
TCI Chemicals (India) | R0211 | Rifabutin | 72559-06-9 | 100MG | ₹7200 | 2022-05-26 | Buy |
TCI Chemicals (India) | R0211 | Rifabutin | 72559-06-9 | 1G | ₹18600 | 2022-05-26 | Buy |
Rifabutin Chemical Properties,Uses,Production
Description
Rifabutin, a rifamycin antibacterial derivative, is the first agent approved and introduced for the prevention of Mycobacterium avium complex (MAC) in AIDS patients. It is also indicated in combination chemotherapy for the prophylaxis and treatment of MAC infections in HIV positive patients and for newly diagnosed and chronic tuberculosis.
Chemical Properties
Red-Brown Powder
Uses
Rifamycins are antibiotics that inhibit DNA-dependent RNA polymerases and are usually bactericidal against Gram-positive bacteria but bacteriostatic against Gram-negative bacteria. Rifamycins are also effective against Mycobacterium species, including M. tuberculosis. Rifabutin is a broad-spectrum rifamycin antibiotic that has applications against tuberculosis, H. pylori, M. avium complex, Chlamydia, and other bacteria. It is also useful in co-infections with human immunodeficiency virus, including tuberculosis.
Indications
Rifabutin (Mycobutin), an antibiotic related to rifampin, shares its mechanism of action, that is, inhibition of RNA polymerase. Rifabutin has significant activity in vitro and in vivo against M. avium-intracellular complex (MAC) isolates from both HIV-infected and non–HIV-infected individuals. It has better activity against MAC organisms than rifampin. Rifabutin is active against M. tuberculosis, including some rifampinresistant strains, such as M.leprae and M.fortuitum. It has a spectrum of activity against gram-positive and gramnegative organisms similar to that of rifampin. The molecular basis for resistance to rifabutin is shared by both rifampin and rifabutin; this explains the virtually complete cross-resistance that occurs between these drugs.
Antimicrobial activity
The activity is similar to that of rifampicin, but it is more active against the Mycobacterium avium complex (MIC 0.01–2 mg/L) and several other atypical mycobacteria. It inhibits the replication of human immunodeficiency virus 1 (HIV-1) in concentrations (10 mg/L) that are not toxic to lymphoid cells, but no efficacy on HIV infections has been demonstrated.
Acquired resistance
The frequency of spontaneously resistant mutants in several bacterial species, including M. tuberculosis, M. leprae, Staphylococcus aureus and Chlamydia trachomatis, is somewhat lower than with rifampicin.
Pharmaceutical Applications
Rifabutine; ansamycin. Molecular weight: 847.02.
A semisynthetic spiropiperidyl derivative of rifamycin S, available for oral administration. It is slightly soluble in water and soluble in organic solvents.
Pharmacology
Rifabutin is well absorbed orally, and peak plasma
concentrations are reached in 2 to 3 hours. Because of
its lipophilicity, rifabutin achieves a 5- to 10-fold higher
concentration in tissues than in plasma. The drug has a
half-life range of 16 to 96 hours and is eliminated in
urine and bile.
Rifabutin appears as effective as rifampin in the
treatment of drug-susceptible tuberculosis and is used
in the treatment of latent tuberculosis infection either
alone or in combination with pyrazinamide. Clinical use
of rifabutin has increased in recent years, especially in
the treatment of HIV infection. It is a less potent
inducer of cytochrome 450 enzymes pathways than rifampin
and results in less drug interaction with the
protease inhibitors and nonnucleoside reverse transcriptase
inhibitors. Rifabutin is therefore commonly
substituted for rifampin in the treatment of tuberculosis
in HIV-infected patients. Another important use of rifabutin
in the HIV-infected population is prevention
and treatment of disseminated MAC.
Pharmacokinetics
Oral absorption:12–20%
Cmax 300 mg oral :0.38 mg/L after 3.3 h
Plasma half-life:16 h
Volume of distribution:9.3 L/kg
Plasma protein binding: 85%
absorption and distribution
Oral absorption is rapid but incomplete, with considerable interpatient variation. It is well distributed, concentrations in many organs being higher than that in plasma. The average concentration in lungs is 6.5 times the simultaneous plasma concentration.
Metabolism and excretion
Rifabutin is mainly metabolized to the active desacetyl derivative, although several other oxidation products have been detected in urine, where some 10% of the dose is eliminated. About 30–50% of the dose can be recovered from the feces. Elimination from plasma is biphasic, with a terminal half-life of 45 h. The drug is a weak inducer of hepatic enzymes. The rate of metabolism increases, and the plasma area under the concentration–time curve (AUC) declines as the treatment continues.
Clinical Use
Prevention of infections with M. avium complex in AIDS patients
Treatment of non-tuberculous mycobacterial disease (in combination with other agents)
Rifabutin in combination with other agents has been proposed as a rescue therapy after Helicobacter pylori treatment failures.Although some efficacy has been observed in the treatment of tuberculosis, its use for this condition is not recommended.
Side effects
The adverse effects that most frequently result in discontinuation of rifabutin include GI intolerance, rash, and neutropenia. Rifabutin levels will be increased with concurrent administration of fluconazole and clarithromycin, resulting in anterior uveitis, polymyalgia syndrome, and a yellowish-tan discoloration of the skin (pseudojaundice). Other adverse reactions are similar to those of rifampin, such as hepatitis, red-orange discoloration of body fluids, and drug interactions due to effects on the hepatic P450 cytochrome enzyme system.
Rifabutin Preparation Products And Raw materials
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
Lupin Ltd | +91-8019896181 +91-8019896181 | Maharashtra, India | 93 | 58 | Inquiry |
Shivam Pharma Chemicals | 91-22-26403900 | Maharashtra, India | 656 | 58 | Inquiry |
CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6257 | 58 | Inquiry |
A.J Chemicals | 91-9810153283 | New Delhi, India | 6100 | 58 | Inquiry |
TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6768 | 58 | Inquiry |
Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6739 | 58 | Inquiry |
SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6514 | 58 | Inquiry |
LUPIN LTD | +91 124 4885000 / +91 124 3325000 | New Delhi, India | 191 | 58 | Inquiry |
Vinayak Group | 91-79-40321603 | Gujarat, India | 36 | 58 | Inquiry |
Indogulf Group | 91-22-23455220 | Maharashtra, India | 249 | 58 | Inquiry |
Supplier | Advantage |
---|---|
Lupin Ltd | 58 |
Shivam Pharma Chemicals | 58 |
CLEARSYNTH LABS LTD. | 58 |
A.J Chemicals | 58 |
TCI Chemicals (India) Pvt. Ltd. | 58 |
Pharmaffiliates Analytics and Synthetics P. Ltd | 58 |
SynZeal Research Pvt Ltd | 58 |
LUPIN LTD | 58 |
Vinayak Group | 58 |
Indogulf Group | 58 |
Related articles
- Side-effects of rifabutin
- Similar to rifampicin, rifabutin (also known as ansamycin LM 427) is a derivative of rifamycin S. The most important property ....
- Mar 28,2022
72559-06-9(Rifabutin)Related Search:
1of4
chevron_right